Precision Biosciences (DTIL) Other Non-Current Assets (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Other Non-Current Assets of $203000.0 for Q1 2026, down 99.1% year-over-year from $22.6 million in Q1 2025, and down 1.46% quarter-over-quarter from $206000.0 in Q4 2025.
Precision Biosciences (DTIL) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Other Non-Current Assets for 9 consecutive years, with $203000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 99.1% year-over-year to $203000.0; the TTM figure through Mar 2026 stood at $203000.0 (down 99.1% YoY), while the FY2025 annual figure was $206000.0, down 99.09% from the prior year.
- Other Non-Current Assets eased to $203000.0 in Q1 2026 per DTIL's latest filing, from $206000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $26.3 million in Q3 2025 and bottomed at $203000.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $9.1 million across 5 years, with a median of $3.7 million in 2022.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 9930.67% — and 2026, when it plunged 99.1%.
- Precision Biosciences' Other Non-Current Assets stood at $1.6 million in 2022, then tumbled by 85.54% to $225000.0 in 2023, then surged by 9930.67% to $22.6 million in 2024, then slumped by 99.09% to $206000.0 in 2025, then declined by 1.46% to $203000.0 in 2026.
- Business Quant data shows DTIL's Other Non-Current Assets at $203000.0 in Q1 2026, $206000.0 in Q4 2025, and $26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | 26.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.33 Mn |
| Mar 31, 2026 | 203,000.00 |
| Dec 31, 2025 | 206,000.00 |
| Sep 30, 2025 | 26.34 Mn |
| Jun 30, 2025 | 22.56 Mn |
| Mar 31, 2025 | 22.57 Mn |
| Dec 31, 2024 | 22.57 Mn |
| Sep 30, 2024 | 22.58 Mn |
| Mar 31, 2024 | 238,000.00 |
| Dec 31, 2023 | 225,000.00 |
| Sep 30, 2023 | 234,000.00 |
| Jun 30, 2023 | 619,000.00 |
| Mar 31, 2023 | 2.75 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 9.52 Mn |
| Jun 30, 2022 | 9.33 Mn |
| Mar 31, 2022 | 4.66 Mn |
| Dec 31, 2021 | 4.64 Mn |
| Sep 30, 2021 | 4.22 Mn |
| Jun 30, 2021 | 1.87 Mn |